Literature DB >> 7160423

The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion.

R M Ings, F Nüdemberg, J L Burrows, T A Bryce.   

Abstract

Subjects were each given either a 25, 50 or 100 mg intravenous loading dose of oxpentifylline followed by an intravenous infusion at a constant rate of 1.5 mg/min for 3 h. Plasma levels of oxpentifylline were measured to obtain information on its pharmacokinetics and to establish which of the loading doses gave the most rapid attainment of the steady state plasma levels of intact drug. Oxpentifylline kinetics were best described by a two compartment model giving a characteristic dip in the plasma level versus time curves before steady state was reached when either the 50 or 100 mg loading doses, followed by the constant intravenous infusion, were given. The terminal half-life of oxpentifylline was 1.02 +/- 0.86 h, reflecting a very high clearance of the drug (approx. 3 000 to 6 000 ml/min). The high clearance could be attributed to extrahepatic metabolism occurring in blood which was observed in vitro using whole blood but not plasma. The clearance of a reduced metabolite of oxpentifylline was less than that of the intact drug, although the half-life was similar (0.83 +/- 0.18 h). Of the three loading doses tested, only the highest showed any side effects, these being transient and occurring within a 5 to 10 min period after dosing and appeared to correlate with the high initial plasma levels of the drug. The 25 mg loading dose gave initial plasma levels generally below the final steady state levels, whilst the 50 mg loading was the closest to giving immediate steady state plasma levels of oxpentifylline.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7160423     DOI: 10.1007/bf00637503

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  The partial purification and properties of a human erythrocyte 4-nitroacetophenone reductase.

Authors:  G M Cohen; I R Flockhart
Journal:  Xenobiotica       Date:  1975-04       Impact factor: 1.908

Review 2.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  [Structure of excretion products of 3,7-dimethyl-1-(5-oxo-hemyl)-xanthine (BL 191) in man].

Authors:  H J Hinze; G Bedessem; A Söder
Journal:  Arzneimittelforschung       Date:  1972-07

4.  Metabolite pharmacokinetics: methods for simultaneous estimates of elimination rate constants of a drug and its metabolite. A commentary.

Authors:  K S Pang; J R Gillette
Journal:  Drug Metab Dispos       Date:  1980 Jan-Feb       Impact factor: 3.922

5.  A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation.

Authors:  K C Yeh; K C Kwan
Journal:  J Pharmacokinet Biopharm       Date:  1978-02

6.  Determination of oxpentifylline and a metabolite, 1-(5'-hydroxyhexyl)-3,7-dimethylxanthine, by gas--liquid chromatography using a nitrogen-selective detector.

Authors:  T A Bryce; J L Burrows
Journal:  J Chromatogr       Date:  1980-03-14

7.  Pharmacologic considerations in the therapy of neonatal apnea.

Authors:  J V Aranda; D Grondin; B I Sasyniuk
Journal:  Pediatr Clin North Am       Date:  1981-02       Impact factor: 3.278

  7 in total
  3 in total

1.  A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans.

Authors:  Marie Magnusson; Ingar C Bergstrand; Sven Björkman; Anders Heijl; Bodil Roth; Peter Höglund
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 2.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

3.  Pentoxifylline as an adjunct therapy in children with cerebral malaria.

Authors:  Bertrand Lell; Carsten Köhler; Betty Wamola; Christopher Ho Olola; Esther Kivaya; Gilbert Kokwaro; David Wypij; Sadik Mithwani; Terrie E Taylor; Peter G Kremsner; Charles R J C Newton
Journal:  Malar J       Date:  2010-12-21       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.